Send to

Choose Destination

See 1 citation found by title matching your search:

  • Showing results for TARP[Title] AND Vaccination[Title] AND Associated[Title] AND Slowing[Title] AND PSA[Title] AND Velocity[Title] AND Decreasing[Title] AND Tumor[Title] AND Growth[Title] AND Rates[Title] AND Stage[Title] AND D0[Title] AND Prostate[Title] AND Cancer[Title]. Your search for TARP Vaccination is Associated with Slowing in PSA Velocity and Decreasing Tumor Growth Rates in Pateinets with Stage D0 Prostate Cancer retrieved no results.
Oncoimmunology. 2016 Jul 1;5(8):e1197459. doi: 10.1080/2162402X.2016.1197459. eCollection 2016 Aug.

TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer.

Author information

Vaccine Branch, Center for Cancer Research, NCI , Bethesda, MD, USA.
Genitourinary Malignancies Branch, Center for Cancer Research, NCI , Bethesda, MD, USA.
Cell Processing Section, Department of Transfusion Medicine, NIH Clinical Center , Bethesda, MD, USA.
Developmental Therapeutics Branch, Center for Cancer Research, NCI , Bethesda, MD, USA.
Division of Cancer Prevention, NCI , Bethesda, MD, USA.
Biostatistics and Data Management Section, Center for Cancer Research, NCI , Bethesda, MD, USA.
Laboratory of Molecular Biology, Center for Cancer Research, NCI , Bethesda, MD, USA.


T-cell receptor alternate reading frame protein (TARP) is a 58-residue protein over-expressed in prostate and breast cancer. We investigated TARP peptide vaccination's impact on the rise in PSA (expressed as Slope Log(PSA) or PSA Doubling Time (PSADT)), validated tumor growth measures, and tumor growth rate in men with Stage D0 prostate cancer. HLA-A*0201 positive men were randomized to receive epitope-enhanced (29-37-9V) and wild-type (27-35) TARP peptides administered as a Montanide/GM-CSF peptide emulsion or as an autologous peptide-pulsed dendritic cell vaccine every 3 weeks for a total of five vaccinations with an optional 6th dose of vaccine at 36 weeks based on immune response or PSADT criteria with a booster dose of vaccine for all patients at 48 and 96 weeks. 41 patients enrolled with median on-study duration of 75 weeks at the time of this analysis. Seventy-two percent of patients reaching 24 weeks and 74% reaching 48 weeks had a decreased Slope Log(PSA) compared to their pre-vaccination baseline (p = 0.0012 and p = 0.0004 for comparison of overall changes in Slope Log(PSA), respectively). TARP vaccination also resulted in a 50% decrease in median tumor growth rate (g): pre-vaccine g = 0.0042/day, post-vaccine g = 0.0021/day (p = 0.003). 80% of subjects exhibited new vaccine-induced TARP-specific IFNγ ELISPOT responses but they did not correlate with decreases in Slope Log(PSA). Thus, vaccination with TARP peptides resulted in significant slowing in PSA velocity and reduction in tumor growth rate in a majority of patients with PSA biochemical recurrence.


PSA biochemical recurrence; Prostate cancer; TARP; therapeutic cancer vaccine

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center